Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection

Medicine & Life Sciences

• GSK1265744 100%
• HIV Integrase Inhibitors 87%
• Rilpivirine 85%
• HIV Infections 46%
• Injections 30%
• HIV 18%
• bictegravir 10%
• Therapeutics 8%
• dolutegravir 8%
• Injection Site Reaction 7%
• Glucuronosyltransferase 6%
• Uridine 6%
• Clinical Pharmacology 6%
• Safety 6%
• Carbamazepine 5%
• Intramuscular Injections 5%
• Mutation 5%
• Rifampin 5%
• Cations 5%
• United States Food and Drug Administration 5%
• Drug Interactions 5%
• Treatment Failure 5%
• Half-Life 4%
• Maintenance 3%
• Randomized Controlled Trials 3%
• Clinical Trials 3%
• Pain 3%
• DNA 2%